Subjects who have developed SARS-CoV-2 specific IgM-S after vaccination show a longer humoral immunity and a lower frequency of infection

We analysed anti-SARS-CoV-2 spike (S) protein (IgG-S), anti-nucleocapsid IgG (IgG-N) and anti-Spike IgM (IgM-S) in 1872 vaccinees at the first dose (D1; w0), after three weeks at the second dose (D2; w3) at three (w6) and 23 weeks (w29) after D2; 109 subjects where further tested at the booster dose (D3, w44), at three weeks (w47) and six months (w70) after D3. Two-level linear regression models were used to evaluate the differences in IgG-S levels.本研究针对1872名疫苗接种者，分别在首剂接种（D1，第0周）、第二剂接种后3周（D2，第3周）、第二剂后3周（w6）以及第二剂后23周（w29）四个时间点，检测其抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突（S）蛋白免疫球蛋白G（IgG-S）、抗核衣壳免疫球蛋白G（IgG-N）与抗刺突免疫球蛋白M（IgM-S）的水平；另有109名受试者在加强针接种（D3，第44周）、加强针后3周（w47）以及加强针后6个月（w70）接受了追加检测。本研究采用两水平线性回归模型评估IgG-S水平的差异。